Neurobiology of Disease, 2015 Background and purpose: Edema formation, inflammation and increased blood–brain barrier permeability contribute to poor outcomes after intracerebral hemorrhage (ICH).
Loretta O. Iniaghe +5 more
doaj +1 more source
Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
Dermatology Reports, 2021 Psoriasis is a chronic condition for which multiple therapies are currently available. In particular, in cases of moderate-severe psoriasis, traditional systemic drugs or the new biological drugs can be administered.
Martina Burlando +3 more
doaj +1 more source
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes
Redox Biology, 2015 Oxidative stress contributes to pathology associated with inflammatory brain disorders and therapies that upregulate antioxidant pathways may be neuroprotective in diseases such as multiple sclerosis.
He Huang +2 more
doaj +1 more source
Proteome-wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress [PDF]
, 2018 Reactive oxygen species (ROS) are increasingly recognised as important signalling molecules through oxidation of protein cysteine residues. Comprehensive identification of redox-regulated proteins and pathways is crucial to understand ROS-mediated events.
Gottlieb, Eyal +4 more
core +2 more sources
USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
Неврология, нейропсихиатрия, психосоматика, 2016 The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral
V. R. Mkrtchyan +3 more
doaj +1 more source
Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. [PDF]
, 2019 Ensaio clínico PROTEC, Protocolo nº 109MS408Abstract BACKGROUND: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease.
Berger, T +5 more
core +1 more source
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
Pharmaceuticals, 2020 COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and ...
Cara A. Timpani, Emma Rybalka
doaj +1 more source
Pharmacology and clinical drug candidates in redox medicine [PDF]
, 2015 SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I +11 more
core +3 more sources
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis [PDF]
, 2020 Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis ...
Amormino, Carola +4 more
core +1 more source
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]
, 2019 A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core +2 more sources